文献速递心外重症与机械循环支持

左心室辅助装置与药物治疗在非卧床心力衰竭患者中的比较:ROADMAP研究中INTERMACS 4级与5至7级患者的分析

Left ventricular assist devices versus medical management in ambulatory heart failure patients: An analysis of INTERMACS Profiles 4 and 5 to 7 from the ROADMAP study.
PubMed 文献 · J Heart Lung Transplant · 2017-12-07

ROADMAP研究再分析按INTERMACS分级分层比较左心室辅助装置(LVAD)与最佳药物治疗(OMM)。两组LVAD不良事件均呈增多趋势。作者认为当前技术下LVAD可能对部分IM4级患者有益,但多数IM5-7级患者可推迟植入并密切随访。

要点

  • IM5-7级主要终点无统计学显著差异,LVAD再住院率93% vs OMM 71%(p=0.016)。
  • 两组合并LVAD不良事件均呈增多趋势,IM5-7级治疗失败频率高需密切随访。

核心结论

  • IM4级LVAD患者较OMM更可能达到主要终点并改善健康相关生活质量与抑郁,尽管不良事件总体更频繁。
  • 当前技术的LVAD治疗可能对部分IM4级患者有益,但多数IM5-7级患者可推迟植入,并因治疗失败频率高而密切随访。

研究设计与样本

  • ROADMAP研究的再分析,按INTERMACS分级将非卧床、非依赖正性肌力药(IM4至7级)患者分为IM4级与IM5-7级两组,比较LVAD与OMM。
  • 评估主要终点(原治疗下1年生存且6分钟步行距离改善≥75米)、实际生存、不良事件与健康相关生活质量。

主要发现

  • 原治疗下2年无事件生存LVAD vs OMM:IM4级67% vs 28%(p<0.001),IM5-7级76% vs 49%(p=0.025)。
  • IM4级LVAD在原治疗下生存且健康相关生活质量或抑郁改善的复合终点优于OMM,IM5-7级则不然。
  • LVAD较OMM不良事件呈增多趋势,两组均如此。
  • 再住院率LVAD vs OMM:IM4级82% vs 86%(p=0.780),IM5-7级93% vs 71%(p=0.016)。

临床怎么用

  • 作者认为当前技术的LVAD治疗可能对部分IM4级患者有益。
  • 作者认为多数IM5-7级患者可推迟LVAD植入,并因治疗失败频率高而密切随访。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ROADMAP study showed survival with improved functional status was better with left ventricular assist device (LVAD) therapy compared with optimal medical management (OMM) in ambulatory, non-inotrope-dependent (INTERMACS [IM] Profile 4 to 7) patients. To study more balanced cohorts and better define which patients may benefit from implantation of an LVAD, we re-evaluated the patients enrolled in ROADMAP when stratified by INTERMACS profile (Profile 4 and Profiles 5 to 7). METHODS: The primary end-point (survival on original therapy with improvement in 6-minute walk distance ≥75 meters at 1 year), actuarial survival, adverse events (AEs) and health-related quality of life (HRQoL) were evaluated. RESULTS: For INTERMACS Profile 4 (IM4), more LVAD patients met the primary end-point compared with OMM patients (40% vs 15%; odds ratio = 3.9 [1.2 to 12.7], p = 0.024), but there was no statistically significant difference for INTERMACS Profiles IM 5 to 7 (IM5-7). Event-free survival on original therapy at 2 years was greater for LVAD than for OMM patients in both IM4 (67% vs 28%; p < 0.001) and IM5-7 (76% vs 49%; p = 0.025) profile groups. Composite end-points of survival on original therapy with improved HRQoL or depression were better with LVAD than OMM in IM4, but not IM5-7. AEs trended higher in LVAD compared with OMM patients in both profile groups. Rehospitalization rates for LVAD vs OMM were similar between treatment arms in IM4 (82% vs 86%; p = 0.780), but were higher for LVAD in IM5-7 (93% vs 71%; p = 0.016). CONCLUSIONS: LVAD patients in IM4, but not IM5-7, are more likely to meet the primary end-point and have improvements in HRQoL and depression compared with OMM, even with AEs generally being more frequent. LVAD therapy with current technology may be beneficial in select IM4 patients, but can be deferred for most IM5-7 patients, who should be followed closely due to the high frequency of treatment failures.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Shah KB, Starling RC, Rogers JG, et al. Left ventricular assist devices versus medical management in ambulatory heart failure patients: An analysis of INTERMACS Profiles 4 and 5 to 7 from the ROADMAP study. J Heart Lung Transplant. 2017. PMID: 29275844. doi:10.1016/j.healun.2017.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。